JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabt… Read more
JW (Cayman) Therapeutics Co. Ltd (JWCTF) - Total Liabilities
Latest total liabilities as of June 2025: $510.83 Million USD
Based on the latest financial reports, JW (Cayman) Therapeutics Co. Ltd (JWCTF) has total liabilities worth $510.83 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JW (Cayman) Therapeutics Co. Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how JW (Cayman) Therapeutics Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
JW (Cayman) Therapeutics Co. Ltd Competitors by Total Liabilities
The table below lists competitors of JW (Cayman) Therapeutics Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Centaur Media Plc
PINK:CAUUF
|
USA | $16.50 Million |
|
Lihtai Construction Enterprise Co Ltd
TWO:5520
|
Taiwan | NT$1.21 Billion |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
Thailand | ฿15.62 Billion |
|
PetroNor E&P ASA
F:FQ00
|
Germany | €51.78 Million |
|
São Carlos Empreendimentos e Participações S.A
SA:SCAR3
|
Brazil | R$1.35 Billion |
|
Empresas la Polar SA
SN:ABC
|
Chile | CL$560.81 Billion |
|
Gohigh Data Networks Technology Co Ltd
SHE:000851
|
China | CN¥3.80 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down JW (Cayman) Therapeutics Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JW (Cayman) Therapeutics Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JW (Cayman) Therapeutics Co. Ltd (2018–2024)
The table below shows the annual total liabilities of JW (Cayman) Therapeutics Co. Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $511.20 Million | +10.59% |
| 2023-12-31 | $462.26 Million | +5.76% |
| 2022-12-31 | $437.06 Million | +34.17% |
| 2021-12-31 | $325.75 Million | -6.86% |
| 2020-12-31 | $349.76 Million | -78.29% |
| 2019-12-31 | $1.61 Billion | +146.32% |
| 2018-12-31 | $654.02 Million | -- |